Genelux Corporation, San Diego Science Center, San Diego, CA, USA.
Bioengineered. 2013 Mar-Apr;4(2):84-9. doi: 10.4161/bioe.22462. Epub 2012 Oct 23.
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is one novel approach for canine cancer therapy. In this study we described for the first time the characterization and the use of new VACV strain LIVP6.1.1 as an oncolytic agent against canine cancer in a panel of four canine cancer cell lines including: soft tissue sarcoma (STSA-1), melanoma (CHAS), osteosarcoma (D-17) and prostate carcinoma (DT08/40). Cell culture data demonstrated that LIVP6.1.1 efficiently infected and destroyed all four tested canine cancer cell lines. In two different xenograft models on the basis of the canine soft tissue sarcoma STSA-1 and the prostate carcinoma DT08/40 cell lines, a systemic administration of the LIVP6.1.1 virus was found to be safe and led to anti-tumor and immunological effects resulting in the significant reduction of tumor growth in comparison to untreated control mice. In summary, the pre-clinical evaluation has demonstrated the efficacy of LIVP6.1.1 for canine cancer therapy. Furthermore, a clinical trial with canine cancer patients has already been started.
溶瘤病毒治疗基于肿瘤溶瘤病毒（VACV）株是一种治疗犬类癌症的新方法。在这项研究中，我们首次描述了新的 VACV 株 LIVP6.1.1 的特性及其作为一种溶瘤剂在包括软组织肉瘤（STSA-1）、黑色素瘤（CHAS）、骨肉瘤（D-17）和前列腺癌（DT08/40）在内的四种犬类癌细胞系中的应用。细胞培养数据表明，LIVP6.1.1 能够有效地感染和破坏所有四种测试的犬类癌细胞系。在基于犬软组织肉瘤 STSA-1 和前列腺癌 DT08/40 细胞系的两个不同的异种移植模型中，全身性给予 LIVP6.1.1 病毒是安全的，并导致抗肿瘤和免疫效应，与未治疗的对照组小鼠相比，肿瘤生长显著减少。总之，临床前评估已经证明了 LIVP6.1.1 用于犬类癌症治疗的疗效。此外，已经开始对犬类癌症患者进行临床试验。
